| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
WMJ-J-09 (compound WMJ-J-09) (0-10 μM, 48 h, CRC cells) (0-20 μM, 72 h, HNSCC cells) selectively kills cancer cells in a concentration- and time-dependent manner, and has no significant toxicity to non-tumor FHC cells [1][2]. WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 48 h, FaDu cells) can arrest the cell cycle of cancer cells at the G2/M phase and induce apoptosis [1][2]. WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) can disrupt microtubule assembly [1][2]. WMJ-J-09 (5 μM, 6-24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) inhibits survivin at the transcriptional level [1][2]. WMJ-J-09 (0-10 μM, 24 h, HCT116 cells) (0-20 μM, 48 h, FaDu cells) modulates signaling pathways in cancer cells, inhibits HDACs to regulate key proteins, and promotes cancer cell apoptosis [1][2].
|
|---|---|
| ln Vivo |
WMJ-J-09 (compound WMJ-J-09) (20 mg/kg, intraperitoneal injection, once daily for 19 days) inhibits CRC tumor growth by inhibiting cancer cell proliferation and is well tolerated in the HCT116 xenograft mouse model [1]. WMJ-J-09 (20 mg/kg, intraperitoneal injection, once daily for 23 days) inhibits the growth of HNSCC xenografts and has good safety [2].
|
| Cell Assay |
Cell viability assay [1][2]
Cell Types: HCT116 cells, FHC cells; FaDu cells, SCC9 cells, SCC25 cells Tested Concentrations: 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, FHC cells); 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells, SCC9 cells, SCC25 cells) Incubation Duration: 48 hours (HCT116 cells, FHC cells); 72 hours (FaDu cells, SCC9 cells, SCC25 cells) Experimental Results: Reduced CRC cell viability (significant inhibitory effect at 10 μM, IC50 approximately 5) The inhibitory effect on cell viability was strongest at 10 μM, with the survival rate of FaDu cells decreasing to approximately 30% after 72 hours of treatment with 20 μM. Apoptosis Analysis [1][2] Cell Types: HCT116 cells; FaDu cells Tested Concentrations: 5 μM (HCT116 cells); 10 μM (FaDu cells) Incubation Duration: 24 h (HCT116 cells); 48 h (FaDu cells) Experimental Results: The proportion of early apoptotic cells (left quadrant) and late apoptotic cells (right quadrant) increased. The cleaved caspase-3 and PARP fragments increased. The proportion of sub-G1 phase cells (apoptotic cells) increased significantly, reaching approximately 40% at a concentration of 20 μM. Cell cycle analysis [1][2] Cell Types: HCT116 cells; FaDu cells Tested Concentrations: 5 μM (HCT116 cells); 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells) Incubation Duration: 24 hours Experimental Results: Decreased the proportion of cells in S phase and increased the proportion of cells in G2/M phase and sub-G1 phase (peak of apoptosis). Increased the proportion of cells in G2/M phase (from 12% to 28% at 10 μM) and decreased the number of cells in S phase.
|
| Animal Protocol |
Animal/Disease Models:A male nude mouse xenograft model of HCT116 was established (4 weeks) [1].
Doses: 20 mg/kg Route of Administration: Intraperitoneal injection (ip) daily for 19 consecutive days, with the same dosage as the control group. Experimental Results: Tumor growth was inhibited; tumor volume and weight were significantly lower than the control group. Tumor proliferation was inhibited, as evidenced by reduced Ki67 immunohistochemical staining within the tumor. Low toxicity; no significant change in mouse body weight. Animal/Disease Models:A Dafu xenograft tumor model was established in male nude mice (4 weeks, 25g) [2]. Doses: 20 mg/kg Route of Administration: Intraperitoneal injection (ip) daily for 23 consecutive days. Experimental Results: Significantly inhibited tumor growth; the average tumor weight in the treatment group was lower than that in the control group. Low toxicity; no significant change in mouse body weight. |
| References |
| Molecular Formula |
C22H27N3O5S
|
|---|---|
| Molecular Weight |
445.53
|
| CAS # |
2416914-29-7
|
| Appearance |
White to off-white solid
|
| SMILES |
O=C(NO)CCCCCCC(NC1=CC(N(S(C2=CC=CC=C2)(=O)=O)CC3)=C3C=C1)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~561.13 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2445 mL | 11.2226 mL | 22.4452 mL | |
| 5 mM | 0.4489 mL | 2.2445 mL | 4.4890 mL | |
| 10 mM | 0.2245 mL | 1.1223 mL | 2.2445 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
